CN104059911B - 具有含氮脂环式骨架的单链核酸分子 - Google Patents

具有含氮脂环式骨架的单链核酸分子 Download PDF

Info

Publication number
CN104059911B
CN104059911B CN201410217512.3A CN201410217512A CN104059911B CN 104059911 B CN104059911 B CN 104059911B CN 201410217512 A CN201410217512 A CN 201410217512A CN 104059911 B CN104059911 B CN 104059911B
Authority
CN
China
Prior art keywords
mentioned
region
bases
nucleic acid
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201410217512.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN104059911A (zh
Inventor
大木忠明
林宏刚
白水久男
滨崎智洋
伊藤彰浩
铃木宽
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bonac Corp
Original Assignee
Bonac Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bonac Corp filed Critical Bonac Corp
Publication of CN104059911A publication Critical patent/CN104059911A/zh
Application granted granted Critical
Publication of CN104059911B publication Critical patent/CN104059911B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3519—Fusion with another nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/51—Methods for regulating/modulating their activity modulating the chemical stability, e.g. nuclease-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/30—Production chemically synthesised

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN201410217512.3A 2010-08-03 2011-07-28 具有含氮脂环式骨架的单链核酸分子 Expired - Fee Related CN104059911B (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
JP2010174915 2010-08-03
JP2010-174915 2010-08-03
JP2010230806 2010-10-13
JP2010-230806 2010-10-13
JP2010-269823 2010-12-02
JP2010269823 2010-12-02
JP2011-152381 2011-07-08
JP2011152381 2011-07-08
CN201180037592.9A CN103052711B (zh) 2010-08-03 2011-07-28 具有含氮脂环式骨架的单链核酸分子

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201180037592.9A Division CN103052711B (zh) 2010-08-03 2011-07-28 具有含氮脂环式骨架的单链核酸分子

Publications (2)

Publication Number Publication Date
CN104059911A CN104059911A (zh) 2014-09-24
CN104059911B true CN104059911B (zh) 2017-01-04

Family

ID=45559420

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201410217512.3A Expired - Fee Related CN104059911B (zh) 2010-08-03 2011-07-28 具有含氮脂环式骨架的单链核酸分子
CN201410217071.7A Expired - Fee Related CN104004018B (zh) 2010-08-03 2011-07-28 具有含氮脂环式骨架的单链核酸分子
CN201180037592.9A Expired - Fee Related CN103052711B (zh) 2010-08-03 2011-07-28 具有含氮脂环式骨架的单链核酸分子

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201410217071.7A Expired - Fee Related CN104004018B (zh) 2010-08-03 2011-07-28 具有含氮脂环式骨架的单链核酸分子
CN201180037592.9A Expired - Fee Related CN103052711B (zh) 2010-08-03 2011-07-28 具有含氮脂环式骨架的单链核酸分子

Country Status (10)

Country Link
US (3) US8691782B2 (enExample)
EP (4) EP2436767B1 (enExample)
JP (3) JP4965745B2 (enExample)
KR (3) KR101849801B1 (enExample)
CN (3) CN104059911B (enExample)
DK (1) DK2674494T3 (enExample)
ES (4) ES2533129T3 (enExample)
PT (1) PT2674494E (enExample)
TW (2) TWI572716B (enExample)
WO (1) WO2012017919A1 (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2533129T3 (es) 2010-08-03 2015-04-07 Bonac Corporation Molécula de ARN monocatenario que tiene esqueleto alicíclico que contiene nitrógeno
WO2013077446A1 (ja) * 2011-11-26 2013-05-30 株式会社ボナック 遺伝子発現制御のための一本鎖核酸分子
EP3254700B1 (en) 2012-03-04 2019-10-23 Bonac Corporation Micro-rna inhibitor
WO2013133393A1 (ja) * 2012-03-07 2013-09-12 学校法人東京医科大学 Ｖｅｇｆ遺伝子の発現抑制用一本鎖核酸分子
JP6283859B2 (ja) * 2012-03-29 2018-02-28 国立大学法人九州大学 ペリオスチン遺伝子の発現抑制核酸分子、ペリオスチン遺伝子の発現抑制方法、およびその用途
US9663784B2 (en) 2012-05-26 2017-05-30 Bonac Corporation Single-stranded nucleic acid molecule for regulating expression of gene having delivering function
WO2015046451A1 (ja) * 2013-09-27 2015-04-02 株式会社アクアセラピューティクス 眼科疾患を除くペリオスチン発現に起因する疾患用医薬、およびその用途
WO2015093495A1 (ja) * 2013-12-16 2015-06-25 株式会社ボナック ＴＧＦ－β１遺伝子発現制御のための一本鎖核酸分子
WO2015099122A1 (ja) 2013-12-26 2015-07-02 学校法人東京医科大学 遺伝子発現制御のための人工ミミックｍｉＲＮＡおよびその用途
SG10201805087VA (en) * 2013-12-27 2018-07-30 Bonac Corp Artificial match-type mirna for controlling gene expression and use therefor
WO2015099188A1 (ja) * 2013-12-27 2015-07-02 株式会社ボナック 遺伝子発現制御のための人工マッチ型ｍｉＲＮＡおよびその用途
HK1244035A1 (en) * 2014-12-15 2018-07-27 Bonac Corporation Single-stranded nucleic acid molecule for inhibiting tgf- beta 1 expression
WO2016104775A1 (ja) 2014-12-27 2016-06-30 株式会社ボナック 遺伝子発現制御のための天然型ｍｉＲＮＡおよびその用途
HK1244030A1 (en) * 2014-12-29 2018-07-27 东丽株式会社 Composition containing nucleic acid molecule stably
JP6602847B2 (ja) 2015-03-27 2019-11-06 株式会社ボナック デリバリー機能と遺伝子発現制御能を有する一本鎖核酸分子
JPWO2016167366A1 (ja) * 2015-04-17 2018-04-05 国立大学法人 東京大学 眼疾患治療剤
EP3369816B1 (en) 2015-10-30 2024-03-13 Toray Industries, Inc. Composition stably containing single-stranded nucleic acid molecule that suppresses expression of tgf-beta1 gene
JP6634095B2 (ja) * 2015-12-29 2020-01-22 国立大学法人北海道大学 プロレニン遺伝子またはプロレニン受容体遺伝子の発現を抑制する一本鎖核酸分子およびその用途
EP3409779A4 (en) * 2016-01-26 2019-07-03 Nissan Chemical Corporation Single-stranded oligonucleotide
WO2017131237A1 (ja) * 2016-01-30 2017-08-03 株式会社ボナック 人工単一ガイドｒｎａ及びその用途
ES2853732T3 (es) * 2016-04-26 2021-09-17 Sumitomo Chemical Co Método de producción de un monómero para una molécula de ácido nucleico monocatenario
JP7188087B2 (ja) * 2017-02-06 2022-12-13 日産化学株式会社 一本鎖オリゴヌクレオチド
US20200038427A1 (en) 2017-03-31 2020-02-06 Bonac Corporation Cyclic nucleic acid molecule having gene expression control function
WO2018199338A1 (ja) * 2017-04-27 2018-11-01 国立大学法人広島大学 Ｂ型肝炎治療用核酸分子
WO2019022257A1 (ja) * 2017-07-28 2019-01-31 杏林製薬株式会社 線維症治療剤
WO2019074110A1 (ja) 2017-10-13 2019-04-18 株式会社ボナック 一本鎖核酸分子およびその製造方法
TWI830718B (zh) * 2018-02-09 2024-02-01 日商住友化學股份有限公司 核酸分子之製造方法
EP3770256A4 (en) 2018-03-20 2021-12-22 Tokyo Institute of Technology ANTISENSE OLIGONUCLEOTIDE WITH REDUCED TOXICITY
US20210115485A1 (en) * 2018-03-30 2021-04-22 Sumitomo Chemical Company, Limited Method for producing single-strand rna
EP3778886A4 (en) 2018-03-30 2022-11-02 Toray Industries, Inc. Method for producing hairpin single-stranded rna molecule
US11401296B2 (en) 2018-04-24 2022-08-02 Sumitomo Chemical Company, Limited Amidite compound and method for producing polynucleotide using said compound
CN112673102A (zh) * 2018-10-02 2021-04-16 东丽株式会社 发夹型单链rna分子的制备方法
WO2020152869A1 (ja) 2019-01-25 2020-07-30 杏林製薬株式会社 線維症治療剤
WO2020202952A1 (ja) 2019-03-29 2020-10-08 住友化学株式会社 無機多孔質担体、及びこれを用いた核酸の製造方法
JP7368456B2 (ja) 2019-03-29 2023-10-24 住友化学株式会社 無機多孔質担体、及びこれを用いた核酸の製造方法
US12371451B2 (en) 2019-03-29 2025-07-29 Sumitomo Chemical Company, Limited Inorganic porous carrier and method for producing nucleic acids using same
US12378275B2 (en) 2019-03-29 2025-08-05 Sumitomo Chemical Company, Limited Porous inorganic carrier and method for producing nucleic acid using same
EP3950695A4 (en) 2019-03-29 2023-01-25 Sumitomo Chemical Company, Limited PROCEDURE FOR PRODUCTION OF RNA
CN114502566B (zh) 2019-10-11 2025-02-11 住友化学株式会社 核酸寡聚物的制造方法
CN115003680B (zh) 2020-01-29 2025-01-28 住友化学株式会社 制备核酸寡聚物的方法
KR20220133878A (ko) 2020-01-29 2022-10-05 스미또모 가가꾸 가부시끼가이샤 핵산 올리고머의 제조 방법
CN115335387A (zh) * 2020-03-27 2022-11-11 住友化学株式会社 核酸寡聚物的制造方法
EP4151597B1 (en) 2020-05-13 2026-04-15 Sumitomo Chemical Company, Limited Inorganic porous substrate, inorganic porous support, and nucleic acid production method
KR20230034969A (ko) 2020-07-09 2023-03-10 스미또모 가가꾸 가부시끼가이샤 핵산 올리고머의 제조 방법
KR20230074205A (ko) * 2020-09-24 2023-05-26 스미또모 가가꾸 가부시끼가이샤 핵산 올리고머의 제조 방법
EP4410770A4 (en) 2021-09-28 2026-03-25 Sumitomo Chemical Co PROCESS FOR THE PRODUCTION OF PURIFIED DICHLOROACETIC ACID
EP4488282A4 (en) 2022-03-23 2025-11-19 Sumitomo Chemical Co PROCESS FOR THE PRODUCTION OF NUCLEIC ACID OLIGOMERS

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003072745A2 (en) * 2002-02-22 2003-09-04 Eshleman James R Antigene locks and therapeutic uses thereof
WO2006088490A2 (en) * 2004-06-30 2006-08-24 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising a non-phosphate backbone linkage
CN1860228A (zh) * 2003-09-30 2006-11-08 安琪士摩奇株式会社 订书钉型寡核苷酸及包含该订书钉型寡核苷酸的药物

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US5631148A (en) 1994-04-22 1997-05-20 Chiron Corporation Ribozymes with product ejection by strand displacement
GB9621367D0 (en) * 1996-10-14 1996-12-04 Isis Innovation Chiral peptide nucleic acids
US6509323B1 (en) 1998-07-01 2003-01-21 California Institute Of Technology Linear cyclodextrin copolymers
FR2790757B1 (fr) 1999-03-09 2003-08-01 Bioalliance Pharma Oligonucleotides contenant une sequence antisens stabilises par une structure secondaire et compositions pharmaceutiques les contenant.
US6962906B2 (en) * 2000-03-14 2005-11-08 Active Motif Oligonucleotide analogues, methods of synthesis and methods of use
TWI321054B (en) 2000-12-19 2010-03-01 California Inst Of Techn Compositions containing inclusion complexes
EP1627061B1 (en) 2001-05-18 2009-08-12 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA)
WO2003079757A2 (en) 2002-03-20 2003-10-02 Massachusetts Institute Of Technology Hiv therapeutic
EP1857547B2 (en) 2002-08-05 2020-12-02 Silence Therapeutics GmbH Further novel forms of interfering RNA molecules
AU2003256857A1 (en) * 2002-08-08 2004-02-25 Dharmacon, Inc. Short interfering rnas having a hairpin structure containing a non-nucleotide loop
US6936651B2 (en) 2002-12-17 2005-08-30 E. I. Du Pont De Nemours And Company Compatibility improvement in crystalline thermoplastics with mineral fillers
NL1022811C2 (nl) * 2003-02-28 2004-08-31 Fountain Patents B V Systeem en werkwijze voor opslag en transport van zeecontainers.
JP2006522158A (ja) * 2003-04-03 2006-09-28 アルナイラム ファーマシューティカルズ インコーポレイテッド ｉＲＮＡ複合体
JP2008526213A (ja) 2004-12-30 2008-07-24 トッド エム． ハウザー， 自己保護オリゴヌクレオチドを使用する、遺伝子発現を調節するための組成物および方法
US8846697B2 (en) * 2006-05-31 2014-09-30 The Regents Of The University Of California Purine analogs
ES2538217T3 (es) * 2007-03-21 2015-06-18 Brookhaven Science Associates, Llc Composiciones combinadas antisentido de horquilla y métodos para modular la expresión
JP5296328B2 (ja) 2007-05-09 2013-09-25 独立行政法人理化学研究所 １本鎖環状ｒｎａおよびその製造方法
EP2171089B1 (en) * 2007-06-25 2014-01-22 Universität Duisburg-Essen Screening-method for polymorphic markers in htra1 gene in neurodegenerative disorders
US20100317714A1 (en) * 2007-11-29 2010-12-16 Suzhou Ribo Life Science Co., Ltd Complex molecule interfering the expression of target genes and its preparing methods
EP2229186A2 (en) 2007-12-04 2010-09-22 Alnylam Pharmaceuticals Inc. Carbohydrate conjugates as delivery agents for oligonucleotides
US20110159586A1 (en) * 2007-12-07 2011-06-30 Halo-Bio Rnai Therapeutics, Inc. Compositions and methods for modulating gene expression using asymmetrically-active precursor polynucleotides
EP2256191A4 (en) 2008-02-15 2011-07-06 Riken CYCLIC SINGLE NUCLEIC ACID COMPLEX AND METHOD FOR THE PRODUCTION THEREOF
JP2010174915A (ja) 2009-01-27 2010-08-12 Toyota Motor Corp 高圧ガスタンク
JP5449815B2 (ja) 2009-03-26 2014-03-19 住友化学株式会社 偏光板の製造方法
JP2010269823A (ja) 2009-05-21 2010-12-02 British American Tobacco Japan Kk 喫煙品用容器
US20110052666A1 (en) 2009-09-03 2011-03-03 Medtronic, Inc. Compositions, Methods, and Systems for SIRNA Delivery
JP2011152381A (ja) 2010-01-25 2011-08-11 Ucom:Kk 箸置き
JP5555940B2 (ja) 2010-04-14 2014-07-23 国立大学法人佐賀大学 増殖糖尿病網膜症の検出方法および予防・治療剤のスクリーニング方法
WO2011132672A1 (ja) 2010-04-19 2011-10-27 独立行政法人理化学研究所 機能性核酸の安定化法
SG186899A1 (en) 2010-07-08 2013-02-28 Bonac Corp Single-strand nucleic acid molecule for controlling gene expression
ES2533129T3 (es) 2010-08-03 2015-04-07 Bonac Corporation Molécula de ARN monocatenario que tiene esqueleto alicíclico que contiene nitrógeno

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003072745A2 (en) * 2002-02-22 2003-09-04 Eshleman James R Antigene locks and therapeutic uses thereof
CN1860228A (zh) * 2003-09-30 2006-11-08 安琪士摩奇株式会社 订书钉型寡核苷酸及包含该订书钉型寡核苷酸的药物
WO2006088490A2 (en) * 2004-06-30 2006-08-24 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising a non-phosphate backbone linkage

Also Published As

Publication number Publication date
ES2443346T3 (es) 2014-02-19
JPWO2012017919A1 (ja) 2013-10-03
WO2012017919A1 (ja) 2012-02-09
EP2674494B1 (en) 2014-12-17
ES2527660T3 (es) 2015-01-28
US8691782B2 (en) 2014-04-08
EP2674494A1 (en) 2013-12-18
EP2628801A1 (en) 2013-08-21
TWI572716B (zh) 2017-03-01
JP2013138681A (ja) 2013-07-18
CN103052711A (zh) 2013-04-17
EP2639307A2 (en) 2013-09-18
EP2436767A4 (en) 2012-05-09
CN104059911A (zh) 2014-09-24
US20140171633A1 (en) 2014-06-19
US9206422B2 (en) 2015-12-08
TW201219570A (en) 2012-05-16
JP5555346B2 (ja) 2014-07-23
US20120035246A1 (en) 2012-02-09
PT2674494E (pt) 2015-02-27
KR101849801B1 (ko) 2018-04-17
EP2639307A3 (en) 2014-02-05
DK2674494T3 (en) 2015-02-23
EP2639307B1 (en) 2015-03-04
HK1200460A1 (zh) 2015-08-07
ES2533129T3 (es) 2015-04-07
TW201615835A (zh) 2016-05-01
JP2013034470A (ja) 2013-02-21
KR20180040727A (ko) 2018-04-20
KR101894701B1 (ko) 2018-09-04
CN103052711B (zh) 2016-08-03
EP2628801B1 (en) 2015-01-07
US20140171486A1 (en) 2014-06-19
EP2436767A1 (en) 2012-04-04
CN104004018B (zh) 2017-01-04
ES2528285T3 (es) 2015-02-06
KR101894702B1 (ko) 2018-09-04
JP4965745B2 (ja) 2012-07-04
EP2639307A8 (en) 2014-04-30
TWI515294B (zh) 2016-01-01
KR20130095738A (ko) 2013-08-28
CN104004018A (zh) 2014-08-27
KR20180040728A (ko) 2018-04-20
HK1189910A1 (en) 2014-06-20
JP5261677B2 (ja) 2013-08-14
US9200278B2 (en) 2015-12-01
EP2436767B1 (en) 2013-11-20

Similar Documents

Publication Publication Date Title
CN104004018B (zh) 具有含氮脂环式骨架的单链核酸分子
CN102918156B (zh) 用于控制基因表达的单链核酸分子
WO2013077446A1 (ja) 遺伝子発現制御のための一本鎖核酸分子
HK1200460B (en) Single-stranded nucleic acid molecule having nitrogen-containing alicyclic skeleton
HK1181423B (en) Single-strand nucleic acid molecule for controlling gene expression

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20170104

CF01 Termination of patent right due to non-payment of annual fee